Aggarwal Biotech Profile
Key Indicators
- Authorised Capital ₹ 7.00 M
- Paid Up Capital ₹ 6.50 M
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 6.09 Cr
- Revenue Growth 39.94%
- Profit Growth -55.64%
- Ebitda -381.53%
- Net Worth -588.48%
- Total Assets -8.37%
About Aggarwal Biotech
Aggarwal Biotech Private Limited (ABPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 06 September 2019 (Five years and five months 9 days old ). Its registered office is in Alwar, Rajasthan, India.
The Company is engaged in the Plastics Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.00 M and a paid-up capital of Rs 6.50 M.
The company has closed loans amounting to ₹6.09 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Atul Agarwal and Pavan Agrawal serve as directors at the Company.
Company Details
-
Location
Alwar, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U25209RJ2019PTC066212
-
Company No.
066212
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Sep 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Aggarwal Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Agarwal
|
Director | 06-Sep-2019 | Current |
|
Pavan Agrawal
|
Director | 06-Sep-2019 | Current |
Financial Performance of Aggarwal Biotech.
Aggarwal Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 39.94% increase. The company also saw a substantial fall in profitability, with a 55.64% decrease in profit. The company's net worth observed a substantial decline by a decrease of 588.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aggarwal Biotech?
In 2023, Aggarwal Biotech had a promoter holding of 35.00% and a public holding of 65.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹60.90 M
Charges Breakdown by Lending Institutions
- Sidbi : 3.09 Cr
- Others : 3.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Feb 2023 | Others | ₹3.00 Cr | Satisfied |
| 12 Oct 2022 | Sidbi | ₹6.90 M | Satisfied |
| 14 Feb 2020 | Sidbi | ₹2.40 Cr | Satisfied |
How Many Employees Work at Aggarwal Biotech?
Unlock and access historical data on people associated with Aggarwal Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aggarwal Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aggarwal Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.